ImmunityBio, Inc. - Common Stock (IBRX)
Frequently Asked Questions About ImmunityBio, Inc. - Common Stock (IBRX)
Has ImmunityBio partnered with other organizations?
Yes, ImmunityBio has established strategic partnerships and collaborations with various academic institutions, government agencies, and other biotech and pharmaceutical companies. These partnerships are aimed at enhancing research capabilities, sharing resources, and accelerating the development of innovative treatments in the fields of immunotherapy and infectious diseases.
How can someone invest in ImmunityBio?
To invest in ImmunityBio, interested individuals can purchase shares through a brokerage account that allows trading on the Nasdaq stock exchange. Given its public listing under the ticker 'IBRX', shares can be bought and sold just like stocks of any other publicly traded company, subject to market conditions.
How does ImmunityBio engage with investors?
ImmunityBio engages with investors through various channels, including regular earnings calls, investor presentations, press releases, and participation in healthcare conferences. The company aims to maintain transparent communication regarding its financial performance, clinical development progress, and strategic initiatives to keep investors informed and engaged.
How does ImmunityBio's technology work?
ImmunityBio's technology primarily works by harnessing the immune system to recognize and attack cancer cells. Through the development of novel therapies, such as CAR-T cell therapy, and vaccines, ImmunityBio aims to enhance the patient's immune response by training immune cells to identify and destroy abnormal or malignant cells in the body.
Is ImmunityBio publicly traded?
Yes, ImmunityBio, Inc. is publicly traded and listed on the Nasdaq stock exchange under the ticker symbol 'IBRX'. The company became public through a merger with a special purpose acquisition company (SPAC) and has been actively involved in capital raising efforts to support its research and development initiatives.
What achievements has ImmunityBio recently accomplished?
ImmunityBio has recently achieved several milestones, including successful clinical trial results for its vaccine candidates, the initiation of new trials, and advancements in regulatory submissions. These achievements highlight the company's ongoing dedication to innovation and its potential impact on the fields of oncology and infectious diseases.
What are ImmunityBio's future prospects?
The future prospects for ImmunityBio appear promising as the company continues to develop and advance its immunotherapeutic candidates. With ongoing clinical trials, potential new product approvals, and a commitment to innovation, ImmunityBio aims to significantly impact the treatment landscape for cancer and infectious diseases.
What clinical indications are ImmunityBio's products targeting?
ImmunityBio's product candidates are targeting a range of clinical indications primarily in oncology, including pancreatic cancer, mesothelioma, and other solid tumors. Additionally, the company is also working on immunotherapies aimed at infectious diseases such as HIV and COVID-19, demonstrating a broad application of its technologies.
What does ImmunityBio, Inc. do?
ImmunityBio, Inc. is a biotechnology company focused on developing innovative immunotherapies for the treatment of cancer and infectious diseases. The company aims to leverage the body's immune system to recognize and destroy cancer cells and is actively involved in the research and development of novel therapies including vaccines and immune-oncology agents.
What is a key goal of ImmunityBio's immunotherapy approach?
A key goal of ImmunityBio's immunotherapy approach is to achieve durable responses in cancer patients by inducing long-lasting immune memory against tumor cells. By activating and training the immune system, the company seeks to create treatments that not only eradicate existing tumors but also prevent recurrence of the disease.
What is ImmunityBio's vision for the future?
ImmunityBio's vision for the future is to become a leader in immunotherapy by revolutionizing the treatment landscape for cancer and infectious diseases. The company strives to innovate and expand its product pipeline while improving patient outcomes through personalized, effective, and long-lasting therapeutic solutions.
What is the commitment of ImmunityBio regarding research and development?
ImmunityBio is deeply committed to research and development (R&D), allocating significant resources to advance its innovative therapies. The company prioritizes conducting high-quality clinical trials, collaborating with global research networks, and investing in cutting-edge technologies to ensure rigorous testing and improvement of its product candidates.
What is the impact of COVID-19 on ImmunityBio's operations?
The COVID-19 pandemic has influenced ImmunityBio's operations, prompting the company to redirect some of its research efforts towards developing therapies and vaccines for COVID-19. This pivot demonstrates their adaptability in addressing urgent global health challenges while continuing to advance its core pipeline of cancer therapies.
What is the main focus of ImmunityBio's research?
The main focus of ImmunityBio's research is on immune-oncology, which includes the development of therapies that activate and enhance the immune system's ability to fight tumors. Additionally, the company explores treatment options for infectious diseases, particularly in addressing immune responses to viral infections.
What is the significance of ImmunityBio's NANT cancer vaccine?
The NANT cancer vaccine is a key component of ImmunityBio's therapeutic pipeline. It is designed to stimulate an immune response against tumor cells by using a personalized approach to enhance the body's ability to target and destroy cancer. The NANT vaccine has shown promise in clinical trials and is a pivotal element in the company’s strategy to improve cancer treatment outcomes.
What role does patient involvement play in ImmunityBio's clinical trials?
Patient involvement in ImmunityBio's clinical trials is crucial as patients who participate contribute to advancing medical research and may gain access to innovative therapies before they are widely available. The company aims to ensure that clinical trial protocols are designed with patient needs in mind, fostering patient engagement and enhancing outcomes.
What type of clinical trials does ImmunityBio conduct?
ImmunityBio conducts a variety of clinical trials, including Phase 1, 2, and 3 trials aimed at evaluating the safety and efficacy of its immunotherapies. These trials are designed to assess new treatments in patients suffering from various forms of cancer and infectious diseases, often focusing on both standalone therapies and combination treatments.
What types of products does ImmunityBio provide?
ImmunityBio focuses on the development of therapeutic agents primarily in the form of immunotherapies and vaccines. Their product portfolio includes candidates intended for the treatment of various types of cancer, such as solid tumors, as well as therapies aimed at preventing and treating infectious diseases.
Where is ImmunityBio, Inc. located?
ImmunityBio, Inc. is headquartered in Culver City, California. The company operates in various facilities equipped with advanced biotechnology research capabilities and also collaborates with other research institutions and organizations to enhance its efforts in immunotherapy.
Who founded ImmunityBio?
ImmunityBio was founded by Dr. Patrick Soon-Shiong, a surgeon, entrepreneur, and biotechnology leader. He is known for his work in the field of medicine and innovation, having previously founded several successful healthcare-related companies and has been a proactive advocate for advancing cancer treatments through immunotherapy.
What is the current price of ImmunityBio, Inc. - Common Stock?
The current price of ImmunityBio, Inc. - Common Stock is 2.840
When was ImmunityBio, Inc. - Common Stock last traded?
The last trade of ImmunityBio, Inc. - Common Stock was at 2:55 pm EDT on April 4th, 2025
What is the market capitalization of ImmunityBio, Inc. - Common Stock?
The market capitalization of ImmunityBio, Inc. - Common Stock is 1.11B
How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
ImmunityBio, Inc. - Common Stock has 391.16M shares outstanding.